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Abstract
Introduction The detection of peripheral blood circulating tumor
cells (CTCs) and bone marrow disseminated tumor cells (DTCs)
in breast cancer patients is associated with a high incidence of
disease relapse and disease-related death. Since hypoxia-
inducible factor-1α (HIF-1α) and vascular endothelial growth
factor (VEGF) play an important role in angiogenesis and tumor
progression, the purpose of the current study was to investigate
their expression in CTCs.
Methods The expression of cytokeratins (CK), VEGF, vascular
endothelial growth factor receptor-2 (VEGF2), HIF-1α and
phosphorylated-focal adhesion kinase (pFAK) in CTCs from 34
patients with metastatic breast cancer who had detectable CK-
19 mRNA-positive CTCs was assessed using double staining
experiments and confocal laser scanning microscopy.
Peripheral blood mononuclear cells (PBMCs) were stained with
a monoclonal A45-B/B3 pancytokeratin antibody in combination
with either VEGF or VEGFR2 or HIF-1α or pFAK antibodies,
respectively.
Results pFAK expression in circulating tumor cells was
detected in 92% of patients whereas expression of VEGF,
VEGF2 and HIF-1α was observed in 62%, 47% and 76% of
patients, respectively. VEGF, VEGF2, HIF-1α and pFAK were
expressed in 73%, 71%, 56% and 81%, respectively, of all the
detected CTCs. Vascular endothelial growth mRNA was also
detected by quantitative real-time RT-PCR in
immunomagnetically-separated CTCs. Double and triple
staining experiments in cytospins of immunomagnetically-
isolated CTCs showed that VEGF co-expressed with HIF-1α
and VEGF2.
Conclusions The expression of pFAK, HIF-1α, VEGF and
VEGF2 in CTCs of patients with metastatic breast cancer could
explain the metastatic potential of these cells and may provide a
therapeutic target for their elimination.
Introduction
The development of metastasis is mainly responsible for can-
cer-related death. Malignant cells detached from the primary
tumor possessing advantageous biological characteristics are
presumed to generate distant disease sites. Indeed, it has
been shown that metastasis is associated with the presence
of circulating (CTCs) and disseminated (DTCs) tumor cells in
peripheral blood and bone marrow, respectively, of otherwise
metastasis-free patients [1,2]. Several studies have reported
that the detection of CTCs and DTCs represents a strong and
independent prognostic factor for a decreased disease-free
and overall survival [3-5]. In addition, recent studies have
shown that in patients with metastatic breast cancer, the
assessment of CTCs is an earlier and more reliable marker
than that of DTCs, associated with disease prognosis and suit-
able for monitoring of tumor response to chemotherapy [6].
CTCs: circulating tumor cells; HIF-1α: hypoxia inducible factor 1 alpha; HUVEC: human umbilical vein endothelial cells; PBMCs: peripheral blood 
mononuclear cells; PBS: Phosphate Buffered Saline solution; pFAK: phosphorylated-focal adhesion kinase; RT-PCR: reverse transcription-polymer-
ase chain reaction; VEGF: vascular endothelial growth factor; VEGFR2: vascular endothelial growth factor receptor 2.Breast Cancer Research    Vol 11 No 6    Kallergi et al.
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Angiogenesis, primarily regulated by vascular endothelial
growth factor (VEGF), is a critical event in tumor progression
and metastasis [7]. Tumor cells produce and release vascular
endothelial growth factor in response to oxygen and nutrients
deprivation that in turn stimulates the formation of new vessels
and promotes tumor growth and dissemination [8]. Besides its
role in new blood formation, VEGF has been also shown to
stimulate the proliferation of tumor cells. Indeed, VEGF
enhanced the proliferation and the migration of breast cancer
cells [9,10], whereas siRNA targeting of VEGF in MCF7
breast cancer cell line, effectively inhibited cell proliferation
and enhanced apoptosis [11]. Moreover, VEGF expression in
breast cancer cells was correlated with decreased response
to hormone treatment [9] and with reduced survival in breast
cancer patients [12]. Focal adhesion kinase (FAK) and Src
catalytic activities are important in promoting VEGF-induced
tumor angiogenesis [13] whereas the inhibition of FAK
reduces VEGF expression resulting in small avascular tumors
in mice [14].
VEGFR2 is the main receptor for VEGFs and its action is
related to the activation of signalling molecules such as
PLCγ1, phosphoinositide-3 kinase (PI-3 kinase), Akt, Src and
ERK [15].
The expression of VEGF in cancer cells is under the control of
hypoxia-inducible factor-1α (HIF-1α) which is a transcription
factor induced under hypoxia conditions [16]. In the absence
of oxygen, HIF-1α binds to hypoxia-response elements induc-
ing the transcription of VEGF gene among other factors such
as LDH-A, NOS, EPO and so on [16]. The expression of HIF-
1α depends on FAK and phosphoinositide-3 kinase (PI-3)
activation in cancer cells [17].
Our group has recently demonstrated that FAK as well as PI-
3 and Akt kinases are phosphorylated and thus activated in
CTCs of breast cancer patients [18,19]. Since FAK is impli-
cated in the angiogenesis process and induces the expression
of VEGF, it was of interest to evaluate whether CTCs from
breast cancer patients have activated the angiogenesis path-
way by expressing HIF-1α and VEGF. This could be an impor-
tant mechanism associated with the metastatic potential of
these cells and therefore could bear important therapeutic
implications.
Materials and methods
Cell cultures
All cell lines were obtained from ATCC (American Type Cul-
ture Collection, USA). The MCF7 mammary adenocarcinoma
cells were cultured in 1:1 (v/v) Dulbecco's Modified Eagle
(DMEM)/Ham's F12 medium (GIBCO-BRL NY, USA), supple-
mented with 10% fetal bovine serum (FBS), 2 mM L-
glutamine, 30 mM NaHCOB3B, 16 ng/ml insulin and 50 mg/ml
penicillin/streptomycin. MDA-MB-231 and human umbilical
vein endothelial cells (HUVEC) cells were cultured in DMEM
10% FBS whereas the MDA-MB-453, SKBR3 and T47D cells
were cultured in RPMI 10% FBS. Subcultivation of all cell lines
was performed with 0.25% trypsin and 5 mM EDTA. These
cell lines were used as positive controls for VEGF, vascular
endothelial growth factor receptor 2, HIF-1α and phosphor-
ylated-focal adhesion kinase (pFAK) expression. Cells were
maintained in a humidified atmosphere of 5% COB2B in air. All
experiments were performed during the logarithmic growth
phase of the cells. Fifteen to 20 h prior to the experiments,
cells were transferred to serum-free culture medium contain-
ing only L-glutamine, NaHCOB3B and penicillin/streptomycin.
HUVEC cells were used as a positive control for HIF-1α
expression [20].
Patient samples and cytospin preparation
Blood samples obtained before the initiation of the respective
line of treatment from 34 patients with metastatic breast can-
cer and tumor cells circulating in their peripheral blood as
detected by real-time PCR for Cytokeratin (CK) -19 mRNA
[21], were analyzed. Peripheral blood (10 ml in EDTA) was
drawn from the middle of vein puncture after the first 5 ml of
blood were discarded. This precaution was undertaken in
order to avoid contamination of the sample with epithelial cells
from the skin during sample collection. All patients gave their
informed consent to participate in the study, which has been
approved by the Ethics and Scientific Committees of our insti-
tution.
Peripheral blood mononuclear cells (PBMC) were isolated
with Ficoll-Hypaque density gradient (d = 1,077 g/mol) centrif-
ugation at 1,800 rpm for 30 minutes. PBMCs were washed
three times with Phosphate Buffered Saline solution (PBS)
and centrifuged at 1,500 rpm for 10 minutes. Aliquots of
250,000 cells were centrifuged at 2,000 rpm for two minutes
on glass slides. Cytospins were dried up and stored at -80°C.
Four to five slides were evaluated from the same blood sample
were evaluated for each examined molecule in the corre-
sponding double staining experiments. The results were
expressed as the mean number of CTCs/250,000 PBMCs.
Confocal laser scanning microscopy
The presence of CK-positive cells in PBMCs of cytospin prep-
arations was investigated using the A45-B/B3 (Micromet,
Munich, Germany) mouse antibody (detecting CK8, CK18
and CK19). Cytospins were also double stained with anti-
CD45 (common leukocyte antigen) antibody to exclude possi-
ble illegitimate expression of cytokeratins on hematopoietic
cells. The cytomorphological criteria (high nuclear to cytoplas-
mic ratio, larger than white blood cells and so on) proposed by
Meng et al [22] were used in order to characterize a CK-pos-
itive cell as a CTC. Cytospins from the same patients were
also stained with goat anti-VEGF (R&D Systems, Inc, Minne-
apolis, USA), rabbit anti-VEGFR2 (Cell Signaling, Boston,
USA), rabbit anti-HIF-1α (Santa Cruz, Santa Cruz, CA, USA)
and mouse anti-pFAK (Chemicon, Temecula, CA, USA) anti-Available online http://breast-cancer-research.com/content/11/6/R84
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bodies in double staining experiments and the expression of
these molecules was assessed using confocal laser scanning
microscopy [18] (see additional data file 1). Double staining
experiments validating VEGF, VEGFR2 and HIF-1α expres-
sion in 10 healthy blood donors were also performed as con-
trols. Control experiments for pFAK expression have been
previously described [18].
For double staining experiments PBMC cytospins were fixed
with 3% paraformaldehyde (PFA) for 30 minutes. Cell mem-
brane permeabilization was performed with 0.5% Triton for 10
minutes followed by overnight incubation with blocking buffer
(PBS/1%BSA). Subsequently, slides were stained for cytok-
eratin with the A45-B/B3 antibody and for VEGF, VEGFR2 or
HIF-1α with the corresponding antibodies for 45 minutes.
Cells were then incubated with the appropriate secondary
antibody for one hour. Finally, slides were stained with DAPI
conjugated with antifade (Invitrogen, Carlsbad, CA, USA).
Phospho-FAK (pFAK) staining was performed as previously
described [18]. Samples were analyzed using a confocal laser
scanning microscope module (Leica Lasertechnik, Heidel-
berg, Germany) and images were analyzed with the respective
software.
Triple immunofluoresence for CK/VEGF/HIF-1α and CK/
VEGF/VEGFR2 was also performed. Cells were initially fixed
using 4% formaldehyde for 15 minutes at room temperature
(RT). Permeabilization was achieved with 0.1% Triton X-100
for five minutes at RT. After blocking with PBS supplemented
with 10% (v/v) FBS for 30 minutes, cells were incubated with
the corresponding antibodies for 45 minutes each. Zenon
technology (Fluorescein Isothiocyanate (FITC)-conjugated
IGg1 antibody) (Molecular Probes, Invitrogen, Carlsbad, CA,
USA) was used for CK detection with the A45-B/B3 antibody.
Zenon antibodies were prepared within 30 min before use.
Zenon reagent was incubated with A45-B/B3 for five minutes,
blocking buffer was added for 5 min and the conjugated anti-
bodies were then ready for use.
VEGFR2 was detected using anti-rabbit antibody labelled with
Alexa555 (Molecular Probes, Invitrogen, Carlsbad, CA, USA),
whereas VEGF was detected by anti-mouse antibody (Santa
Cruz, Santa Cruz, CA, USA) labelled with Alexa 633 (Molecu-
lar Probes, Invitrogen, Carlsbad, CA, USA). For CK/VEGF/
HIF-1α staining, zenon technology (FITC-conjugated) was
also used for CK detection. For VEGF, an anti-mouse antibody
labelled with Alexa 633 was used and HIF-1α was stained
with anti-rabbit antibody labelled with Alexa555. Cells incu-
bated with the different antibodies were post-fixed with 4% (v/
v) formadehyde in PBS for 15 minutes at RT. Finally, cells were
stained with DAPI conjugated with antifade.
Immunomagnetic separation of CTCs
In 10 patients with metastatic breast disease, a negative
selection procedure was performed for the isolation of CTCs
according to Naume et al [23]. Briefly, 100 μl of CELLection
beads coated with anti-CD45 monoclonal antibody (Dynal,
Invitrogen, Carlsbad, CA, USA) were added in 107P/ml
PBMCs in PBS/0.1% BSA/2 mM EDTA. PBMCs were iso-
lated from 20 ml of blood using Ficoll density gradient centrif-
ugation. After an incubation for 30 minutes at 4°C, the
supernatant was transferred in FBS-coated tubes and cells
were cyto-centrifuged at 2000 rpm for two minutes on glass
slides. The same number of cells was centrifuged at 1,500
rpm for five minutes and the pellet was stored at -80°C for
RNA extraction.
In control spiking experiments, 10 MCF7 tumor cells (1/106),
100 cells (10/106) and 1,000 cells (100/106) were spiked in
107 PBMCs obtained from healthy volunteers. Subsequently,
100 μl of anti-CD45-beads were added in every 107 PBMCs
according to the manufacturer's instructions and cytospins
were prepared using the isolated cells. By this method, it was
possible to estimate the enrichment of CTCs per 250,000
PBMCs. The proportion of CTC/PBMCs after enrichment was
approximately 1/60 and the obtained degree of CTCs enrich-
ment ranged from 150% to 300%. Moreover, in order to verify
that the tumor cell-depleted PBMCs fraction did not contain
CTCs, immunostaining with A45-B/B3 antibody was per-
formed on cytospins prepared from the CTCs-depleted frac-
tion. Three independent spiking experiments demonstrated
that no CK-positive cells could be identified in these samples.
Immunoblot analysis
MCF7, T47D, SKBR3, MDA-MB-453 and MDA-MB-231 cells
were lysed in 100 μl lysis buffer each (50 mM Tris/HCl, 1%
TritonX-100 pH 7.4, 1% Sodium deoxycholate, 0.1% SDS,
0.15% NaCl, 1 mM EDTA, 1 mM sodium orthovanadate) at
4°C and flasks were scrapped off. The remaining insoluble
material was removed by centrifugation. Protein concentration
of the samples was determined using the Bio-Rad protein kit.
Equal amounts of protein (100 μg) were separated with SDS
electrophoresis and blotted onto nitrocellulose membrane.
Proteins were incubated with anti-VEGF, anti-VEGFR2 and
HIF-1α antibodies for 1 h at room temperature and then with
the appropriate secondary antibody. Detection of protein
bands was succeeded using the ECL kit. Western blots were
quantified using Bio-Rad Quantity One program. The numbers
we provided correspond to the Adj Vol Intensity per mm2 and
the measurements concerned equal square area. Intensity of
the background was set as 0.
Real-time RT-PCR for VEGF quantification
RNA was extracted, from both the immunomagnetically CTC-
enriched and CTC-depleted PBMCs fractions, using the Trizol
reagent (Invitrogen, Carlsbad, CA, USA). The same procedure
was followed for three normal volunteers. Both fractions were
used in order to investigate the relative expression of VEGF
since it could not be excluded that some hemopoietic cells
had contaminated the CTC-enriched fraction. All preparationsBreast Cancer Research    Vol 11 No 6    Kallergi et al.
Page 4 of 12
(page number not for citation purposes)
and handling of RNA took place in a laminar flow hood under
RNase-free conditions. RNA concentration was quantified
with Nanodrop ND-1000 spectophotometer. Afterwards
equal RNA amounts from patients' CTCs-enriched and CTCs-
depleted PBMCs proceeded to cDNA synthesis with Super-
script III platinum kit (Invitrogen, Carlsbad, CA, USA) accord-
ing to manufacturer's instructions. Real-time RT-PCR for
VEGF quantification was performed as previously described
[24].
Results
Patient characteristics
Thirty-four patients with metastatic breast cancer and CK-19
mRNA positive CTCs detected in their peripheral blood [21],
were enrolled in the present study. Patient characteristics are
listed in Table 1. Median age was 57 (range, 30 to 76) years
and 88% of the patients were post-menopausal. Twenty-three
(68%) patients had relapsed after treatment for early breast
cancer. Adjuvant chemotherapy regimens included anthracy-
clines in four patients, taxanes and anthracyclines in 10, Cyclo-
phosphamide, Methotrexate and 5-Fluoruracil (CMF regimen)
in six patients, whereas in three the type of adjuvant chemo-
therapy was unknown. Eighteen (53%) patients had received
no prior chemotherapy for metastatic disease, seven (21%)
had received one and nine (26%) two or more prior lines of
treatment. Patients had not received antiangiogenic agents as
part of their treatment before study entry. Patients with HER2
positive tumors received chemotherapy in combination with
trastuzumab or lapatinib. Second- and third- (or higher) line
regimens administered included anthracyclines or taxanes as
single agents or combinations of docetaxel and capecitabine,
taxanes and antracyclines, vinorelbine and gemcitabine and
vinorelbine in combination with trastuzumab or lapatinib in
patients with HER2 positive tumors.
VEGF and VEGFR2 expression in breast cancer cell lines
In preliminary experiments, we investigated the expression of
VEGF, VEGFR2 HIF-1α and pFAK in breast cancer cell lines.
Among the five examined breast cancer cell lines MDA-MB-
231, MDA-MB-453 and SKBR3 cells are generally consid-
ered more aggressive compared to T47D and MCF7 cells [25-
27]. Immunoblot analysis of equal protein amounts of cell
lysates with anti-VEGF antibody revealed that the less-aggres-
sive cell lines (T47D and MCF7) expressed less VEGF than
the more aggressive cell lines SKBR3, MDA-MB-231 and
MDA-MB-453 cells (Figure 1A). HIF-1α and pFAK was
expressed in all the examined cell lines except MDA-MB-231,
whereas VEGFR2 was mainly expressed in MDA-MB-231
(see additional data file 2).
Subsequently, the sensitivity and specificity of immunofluores-
cence assays for the detection of VEGF, VEGFR2 and HIF-1α
in CTCs were evaluated on cytospins of tumor cells spiked in
PBMCs obtained from healthy volunteers.
VEGF and VEGFR2 expression in CTCs
Using double staining experiments, VEGF-expressing CK-pos-
itive CTCs were detected in 21 (62%) patients (Figure 1BI, II,
III, see also additional data file 3). Among a total of 99 CK-19
positive CTCs recognized in cytospins from all patients, 72
(73%) stained positively for both VEGF and CK (Figure 1C)
showing that the majority of the detected CTCs expressed
VEGF in their cytoplasm. Moreover, in 12 (35%) patients all
the detected CTCs expressed VEGF in their cytoplasm. The
median percentage of CTCs expressing VEGF among the 34
patients was 100% (range; 29% to 100%).
Consequently, VEGFR2-expressing CK+ CTCs were identi-
fied in 16 (47%) out of 34 patients (Figure 2AIII, see also addi-
tional data file 3). Among a total of 124 CK+ CTCs detected in
all studied patients, 89 (71%) were double stained [(CK(+)/
VEGFR2(+)] (Figure 1C). In only four (12%) patients, all the
detectable CTCs expressed VEGFR2. The median expression
of VEGFR2 on CTCs identified per patient was 75% (range,
10% to 100%). Confocal laser scanning microscopy revealed
that VEGFR2 was mainly localized adjacent to the plasma
membrane (Figure 2AI); however, in some CTCs, VEGFR2
was also intracellulary distributed (Figures 2AII, 3BI and 3CI).
Spearman's analysis showed a significant correlation (P  =
0.042) between the number of VEGF- and VEGFR2-express-
ing CTCs in the whole group of patients. No double positive
cells (CK+VEGF+ or CK+VEGFR2+) could be observed in
healthy volunteers (n = 10 normal blood donors), although
VEGF and VEGFR2 expression was detected in some hemat-
opoietic cells.
The expression of either VEGF or VEGFR2 on CTCs did not
correlate with ER/PR or HER2 status of the primary tumor. In
addition, no correlation was found between VEGF and
VEGFR2 expression and line of treatment (no prior regimens
vs one or more regimens for metastatic disease) or response
to treatment.
Expression of HIF-1α and phosphorylated FAK in CTCs
VEGF expression is under the regulation of HIF-1α transcrip-
tion factor and of FAK [28]. In order to determine whether ang-
iogenic pathways including HIF-1α and FAK operate on
CTCs, the expression of these molecules was assessed using
double staining experiments in patient's cytospins.
Figure 2BIII demonstrates that 26 (76%) out of 34 patients
had HIF-1α+/CK+-positive cells. HIF-1α is distributed both in
the cytoplasm and in the nucleus of the majority of CTCs (Fig-
ure 2BI and 2BII, see also additional data file 3). In nine (26%)
patients, all the detected CTCs expressed HIF-1α; the median
proportion of cells expressing HIF-1α was 69% (range; 5% to
100%). Among a total of 223 CK-positive cells detected in all
studied patients, 125 (56%) were double-positive (CK+/HIF-
1α+) (Figure 1C). HIF-1α-positive CTCs co-exist with VEGF-Available online http://breast-cancer-research.com/content/11/6/R84
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Table 1
Patient characteristics
Age
Median (range) 57 (30 to 76)
n (%)
Menopausal status
Premenopausal 4 (12)
Postmenopausal 30 (88)
Primary breast cancer at presentation 23 (68)
Tumor size (cm)
1-1.9/2-4.9/≥5/UN 3 (13)/14 (61)/2 (9)/4 (17)
Lymph nodes
0/1-3/≥4/UN 7 (30)/6 (26)/8 (35)/2 (9)
Grade
II/III/UN 8 (35)/11 (48)/4 (17)
Disease sites*
1 5 (15)
2 15 (44)
3 5 (15)
≥4 8 (23)
Unknown 1 (3)
Predominantly visceral disease
Yes 11 (32)
No 22 (64)
Unknown 1 (3)
Line of treatment **
0 18 (53)
1 7 (21)
≥2 9 (26)
ER/PR status
Positive 16 (47)
Negative 13 (38)
Unknown 5 (15)
HER2 status
Positive*** 7 (20)
Negative 23 (68)
Unknown 4 (12)
UN = unknown,
* Numbers correspond to the number of organs involved
** Numbers correspond to the number of prior therapies administered for metastatic disease
*** IHC:3+ or FISH positiveBreast Cancer Research    Vol 11 No 6    Kallergi et al.
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or VEGFR2-positive CTCs in 16 (47%) and 14 (41%) breast
cancer patients, respectively.
Double staining experiments in the control group of 10 healthy
blood donors (n = 10), revealed no CK-positive cells express-
ing HIF-1α in their PBMCs, whereas this transcription factor
was expressed in some hematopoietic cells.
We have recently reported that pFAK was expressed in all CK-
positive CTCs of patients with early breast cancer [18]. In the
present study we investigated the expression of pFAK in 12
patients with metastatic disease for whom adequate material
was available. Double staining experiments revealed that
pFAK was expressed in 92% (11 out of 12) of the CTCs-pos-
itive patients (Figure 3AI and 3AII). Among a total of 26 CK+
CTCs, 21 (81%) were double stained (CK+pFAK+) (Figure
1C). In eight (67%) out of 12 patients, all their CTCs were
pFAK-positive. All of these patients also had HIF-1α-positive
CTCs (Spearman's rho correlation analysis P < 0.001). The
median percentage of cells expressing pFAK was 100%
(range 50% to 100%). No correlation was also found between
the expression of HIF-1α on CTCs and ER/PR or HER2 status
of the tumor as well as with the line of treatment or response
to treatment.
Figure 1
Vascular endothelial growth factor expression in breast cancer cell lines and in circulating tumor cells Vascular endothelial growth factor expression in breast cancer cell lines and in circulating tumor cells. A: VEGF, VEGFR2 HIF-1α and pFAK expres-
sion in cultured breast cancer cell lines, 1: MCF7, 2:T47D, 3: SKBR3 4:MDA MB-453, 5: MDA MB-231 (western blot analysis of equal protein 
amount of cell lysates). B (I): Representative images of confocal laser scanning microscopy of PBMCs cytospins stained with pancytokeratins A45 
B/B3 (green), and VEGF anti-goat (red) antibodies. B (II): Representative images of PBMCs cytospins stained with pancytokeratins A45 B/B3 
(green), VEGF anti-goat (red) antibodies and Dapi (blue). B (III): Quantification of VEGF and CK co-expression in CTCs of 34 metastatic breast can-
cer patients. All the examined patients (100%) presented CTCs in their blood, while 62% also presented double positive cells (VEGF+CK+). (C) 
Quantification of double positive CTCs/total CTCs for each examined molecule in 34 metastatic breast cancer patients. For pFAK testing cytospins 
from 12 patients were evaluated. indicatively. Seventy-three percent of the examined CTCs were VEGF+CK+ positive, 71% were VEGFR2+CK+, 
56% were HIF-1α+CK+ and 81% were pFAK+CK+.Available online http://breast-cancer-research.com/content/11/6/R84
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Negative and positive controls were used in each experiment
for every examined molecule Figure 4A, B and 4C.
Co-expression of VEGF, VEGFR2 and HIF-1α in CTCs
The co-expression of the examined molecules was further ana-
lysed in 10 patients after negative immmunomagnetic separa-
tion. Negative selection was preferred because prior
experiments using MCF7 cells spiked into PBMCs obtained
from healthy donors to estimate recovery yields, revealed
higher recovery rates for negative compared to positive selec-
tion, even in low cell concentrations (one CTC in 106 PBMCs);
moreover, the quality of RNA (ratio 260:280) extracted from
CTCs-enriched and CTCs-depleted cell fractions was supe-
rior after negative compared to positive immunomagnetic
selection (data not shown).
The expression of CK/VEGF, CK/VEGFR2 and CK/HIF-1α
was investigated in PBMCs cytospins before and after
immmunomagnetic separation. Figure 3BI, II shows that VEGF
could be co-localized with VEGFR2 or HIF-1α in the same cell.
In order to further confirm that HIF-1α, VEGF and VEGFR2
were co-expressed in the same CTC and not in residual
PBMCs, triple immunofluorence CK/VEGF/VEGFR2 and CK/
Figure 2
Vascular endothelial growth factor receptor 2 and hypoxia-inducible factor-1α in circulating tumor cells of patients with breast cancer Vascular endothelial growth factor receptor 2 and hypoxia-inducible factor-1α in circulating tumor cells of patients with breast cancer. A (I): Repre-
sentative images of cytospin double stained with monoclonal pancytokeratin (A45-B/B3) (green) and polyclonal VEGFR2 anti-rabbit (red) antibod-
ies. A (II): Representative images of PBMCs cytospins stained with pancytokeratins A45 B/B3 (green), VEGFR2 anti-rabbit (red) antibodies and 
Dapi (blue). A (III): Quantification of VEGFR2 and CK co-expression in CTCs of 34 patients with metastatic breast cancer. CTCs were detected in 
all (100%) patients while in 47% double positive cells (VEGFR2+CK+) were identified. B (I): Representative image of a cytospin double stained with 
monoclonal pancytokeratin (A45-B/B3) (green) and polyclonal HIF-1α (red) antibodies. B (II): Representative images of PBMCs cytospins stained 
with pancytokeratins A45 B/B3 (green), HIF-1α anti-rabbit (red) antibodies and Dapi (blue). B (III): Quantification of HIF-1α and CK co-expression in 
CTCs of 34 patients with metastatic breast cancer. All the examined patients (100%) harvested CTCs in their blood, while 76% also presented dou-
ble positive cells (HIF-1α+CK+).Breast Cancer Research    Vol 11 No 6    Kallergi et al.
Page 8 of 12
(page number not for citation purposes)
VEGF/HIF-1α was performed in the same patients. Figure
3CI, II demonstrates that VEGF is co-expressed with VEGFR2
and HIF-1α in CTCs.
VEGF mRNA expression in CTCs
To determine whether VEGF was produced by the CTC and
not adsorbed from the plasma, RNA extracted from both the
CTCs-enriched and the corresponding CTCs-depleted cell
fractions were analyzed for VEGF using equal RNA amount of
each fraction and quantitative real-time RT-PCR assay as pre-
viously described [24]. A 2-ΔCt method [29] was used to exam-
ine the relative expression of VEGF in CTCs-enriched fraction
compared to the CTCs-depleted fraction.
The results revealed that VEGF mRNA was overexpressed in
four (40%) out of 10 examined patients (compared to corre-
sponding fractions of normal blood donors) with a 3.1-, 8.3-,
11.5- and 25.3-fold increase in the CTCs-enriched cell frac-
tion compared to the CTCs-depleted cell fraction. Double
staining experiments with VEGF and A45/B-B3 antibodies
confirmed the presence of intracytoplasmic VEGF in these
four patients as well as in three additional patients (Table 2).
Discussion
Circulating and disseminated tumor cells derived from the pri-
mary tumor and possessing advantageous biological charac-
teristics could acquire the capability of generating metastasis.
CTCs have significant prognostic value for early and meta-
static breast cancer patients [4,5,30]. These cells are very het-
erogenous and not fully characterized as yet [31,32]. VEGF is
an important angiogenic factor for tumor vascularization. The
expression of VEGF is under HIF-1α control, in hypoxia condi-
Figure 3
Phosphorylated-focal adhesion kinase expression in circulating tumor cells and co-expression of vascular endothelial growth factor/vascular  endothelial growth factor receptor or vascular endothelial growth factor/hypoxia-inducible factor-1α in circulating tumor cells of patients with breast  cancer Phosphorylated-focal adhesion kinase expression in circulating tumor cells and co-expression of vascular endothelial growth factor/vascular 
endothelial growth factor receptor or vascular endothelial growth factor/hypoxia-inducible factor-1α in circulating tumor cells of patients with breast 
cancer. A (I): Representative image of a cytospin double stained with polyclonal pancytokeratin (red) and (monoclonal) pFAK (green) antibodies. A 
(II): Quantification of pFAK and CK co-expression in CTCs of 12 patients with metastatic disease. All the examined patients (100%) presented 
CTCs in their blood, while 92% also presented double positive cells (pFAK+CK+). B: Representative confocal laser scanning micrographs of CTCs 
cytospins after negative immunomagnetic separation in 10 patients with metastatic breast cancer. Cells cytospins were double stained with VEGF 
and either (I) VEGFR2 or (II) HIF-1α antibodies, respectively. C: Representative image of a cytospin, triple stained with monoclonal pancytokeratin 
(A45-B/B3) (green) and VEGF antibodies (blue) along with either (I) VEGFR2 or (II) HIF-1α (B) (red) polyclonal antibodies (red).Available online http://breast-cancer-research.com/content/11/6/R84
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tions [8,11]. In addition, focal adhesion kinase is also an
upstream regulator of VEGF and HIF-1α expression [13,17].
We have recently reported that phosphorylated-FAK was
expressed in CTCs of all CK-positive early breast cancer
patients [18]. In the present study we examined the existence
of angiogenic molecules in CTCs of metastatic breast cancer
patients.
Initially, we evaluated the expression of VEGF in breast cancer
cell lines. As shown in Figure 1, VEGF was expressed in the
cytoplasm of all the examined breast cancer cells. Interest-
ingly, a correlation was evident between VEGF expression and
cell aggressiveness. Specifically, the SKBR3, MDA-MB-231
and MDA-MB-453 cell lines which are highly metastatic [25-
27] expressed higher levels of VEGF compared to MCF7 and
T47D which are estrogen receptor-positive and less aggres-
sive cells. On the contrary, the total protein amount of HIF-1α
didn't follow the same pattern of expression. This is probably
attributed to the fact that cells were cultured under normal oxy-
gen conditions. Moreover, HIF-1α is a transcription factor and
it is possible that its activity relates to its nuclear distribution
rather than the total intracellular amount of protein.
Since VEGF is related to the metastatic potential of cancer
cells, we investigated VEGF expression in CTCs of 34 meta-
static CK-positive breast cancer patients. The results of the
current study revealed that VEGF was expressed in CTCs of
62% of the patients and the great majority (73%) of these cells
were double positive (CK+VEGF+), implying the possible
involvement of VEGF in the metastatic potential of these cells.
Indeed, in the study by Mohammed et al [25-27], VEGF
expression on breast cancer cells was associated with
Figure 4
Vascular endothelial growth factor, vascular endothelial growth factor receptor 2 and hypoxia-inducible factor-1α expression in MCF7, Human umbil- ical vein endothelial cells and MDA-MB-231 respectively Vascular endothelial growth factor, vascular endothelial growth factor receptor 2 and hypoxia-inducible factor-1α expression in MCF7, Human umbil-
ical vein endothelial cells and MDA-MB-231 respectively. A: MCF7 cells stained with pancytokeratin/FITC (green) and VEGF/Alexa555 (red) or 
MCF7 cells stained with pancytokeratin/FITC (green) and just Alexa555 antibody without VEGF antibody (negative control). B: HUVEC cells stained 
with pancytokeratin/FITC (green) and HIF1-α/Alexa555 (red) or HUVEC cells stained with pancytokeratin/FITC (green) and just Alexa555 antibody 
without HIF1-α antibody (negative control). C: MDA-MB-231 cells stained with pancytokeratin/FITC (green) and VEGFR2/Alexa555 (red) or MDA-
MB-231 cells stained with pancytokeratin/FITC (green) and just Alexa555 antibody without VEGFR2 antibody (negative control).Breast Cancer Research    Vol 11 No 6    Kallergi et al.
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aggressive tumor biology as indicated by the significant corre-
lation between VEGF expression, lymph node metastasis, dis-
tant metastasis and poorer survival.
In the present study, VEGF expression in CTCs was further
confirmed by quantitative real-time RT-PCR in immunomagnet-
ically separated CTCs. Indeed, CTCs from four out of 10
patients expressed both VEGF mRNA and VEGF protein.
Immunofluorescence experiments further revealed VEGF pro-
tein expression in three additional patients who did not
express VEGF mRNA. This discrepancy could be attributed to
the different sensitivities of the used assays; alternatively, it is
possible that this growth factor could be absorbed from the
serum.
HIF-1α induces VEGF expression in cells under hypoxic con-
ditions by binding to VEGF promoter [8,33]. Recent studies
have shown that HIF-1α is increased in various carcinomas
and its presence is associated with poor prognosis and resist-
ance to therapy [16,34,35]. Focal adhesion kinase (FAK) is
also important in promoting VEGF-induced tumor angiogen-
esis [13] whereas the expression of HIF-1α depends on FAK
and PI-3 kinase activation in cancer cells [17]. In order to char-
acterize the possible functional pathways leading to the
observed VEGF expression in CTCs we investigated the
expression of HIF-1α and pFAK in patients' CTCs. Double
staining experiments revealed that HIF-1α was expressed in
76% of breast cancer patients and this expression was
observed both in the cytoplasm and the nucleus although, in
general, cytospin preparations are not the optimal material to
study the intracellular distribution of molecules. The intracellu-
lar distribution reported in this study refers to what it was
observed using confocal laser scanning microscopy (Figure
2B). Double (VEGF/HIF-1α) and triple (VEGF/HIF-1α/CK)
staining immunofluoresence experiments after immunomag-
netic enrichment of CTCs, revealed that these molecules can
be co-localized in the same cell (Figure 3BII and 3CII). These
findings denote a possible interaction between VEGF and
HIF-1α in CTCs as it has already been shown in cancer cells
[16]. In addition, our experiments revealed that FAK was phos-
phorylated in the CTCs of the majority (92%) of the examined
CK-positive metastatic breast cancer patients. These results
are in agreement with our previously published data from early
breast cancer patients [18]. Furthermore, all patients with
pFAK-positive CTCs also had detectable HIF-1α positive
CTCs (Spearman's correlation analysis P < 0.001), suggest-
ing the presence of a functional pathway leading to VEGF pro-
duction.
VEGFR2 is the principal receptor through which VEGFs exert
their mitogenic and chemotactic effects [8,36]. In breast can-
cer cell lines VEGF regulates cell growth and survival via an
autocrine loop including the phosphorylation of Akt and ERK1/
2 [15,37]. We have recently shown that Akt was strongly acti-
vated in CTCs both in patients with early and metastatic dis-
ease [19]; however, there are no data in the literature
concerning the expression of VEGFR2 in CTCs. The results of
the current study demonstrate that VEGFR2 was expressed in
CTCs of 47% of breast cancer patients. It is interesting to note
that the proportion of CTCs expressing VEGF or VEGFR2 in
all the tested patients was almost identical (73% and 71%,
respectively; Figure 1C); in addition, there was a statistically
significant correlation between the number of CTCs express-
ing VEGF and VEGFR2 (P = 0.042). These data strongly sug-
gest that patients' CTCs may both produce and consume
VEGF through a putative autocrine mechanism. This assump-
tion is further supported by the observed co-expression of
these molecules (Figures 3BI and 3CI) in CTCs after immu-
nomagnetic enrichment and double (VEGF/VEGFR2) or triple
(VEGF/VEGFR/CK) staining experiments.
Our results also confirmed the heterogeneity of CTCs. Indeed,
the molecules evaluated in the present study were not
expressed in all examined CTCs, even not among those iden-
tified in the same patient. This may explain the fate and the
metastatic potential of cells presenting such a phenotypic
diversity.
Conclusions
The data reported in the present study demonstrate that CTCs
from patients with metastatic breast cancer express VEGF
both at mRNA and protein level. The production of VEGF is
probably under the regulation of HIF-1α and/or pFAK as sug-
gested by the observed significant correlation between the
expression of these molecules. Moreover, we have also dem-
onstrated that VEGFR2 is also expressed on CTCs' mem-
Table 2
VEGF mRNA expression in CTCs of patients with metastatic 
breast cancer
No Patients Ct (CTCs) Ct (PBMCs) 2-ΔCt
1 32,6 30,6 0,3
2 33,7 36,8 8,3
3 24,1 28,7 25,3
4 37,9 38,8 1,8
5 41,0 41,0 1,0
6 39,4 41,0 3,1
7 34,8 32,3 0,2
8 41,0 36,9 0,1
9 35,7 32,2 0,1
10 34,7 38,2 11,5
A 2-ΔCt method was used to examine the relative expression of VEGF 
in CTCs-enriched fraction compared to the CTCs-depleted fraction. 
Equal RNA amount from each fraction was processed for RT-PCR 
and Real-Tme PCR. Ct is the Real-Time PCR sample threshold cycle 
and ΔCt is (Ct(CTCs)- Ct(PBMCs)), PBMCs are the Peripheral Blood 
Mononuclear Cells (the CTCs-depleted fraction).Available online http://breast-cancer-research.com/content/11/6/R84
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brane suggesting an autocrine loop involving VEGF and
VEGFR2. The biologic significance of the presence of ang-
iogenic molecules on CTCs is currently unknown. However,
based on previous evidence, one might hypothesize that ang-
iogenic pathways present on CTCs could result in evasion of
apoptosis, enhancement of metastatic potential [10] and
resistance to endocrine therapy [38]. In addition, the expres-
sion of angiogenic molecules on CTCs could be indicative of
the tumor dependence on angiogenesis. Accordingly, anti-
VEGF and/or anti-VEGFR2 targeting agents might have ther-
apeutic implications in patients with VEGF- and VEGFR2-
expressing CTCs.
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